Alerts will be sent to your verified email
Verify Email
ZIMLAB
|
Zim Laboratories
|
Medicamen Biotech
|
Prevest Denpro
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
7.0 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
7.41 % | 8.49 % | 23.02 % |
|
5yr average Equity Multiplier
|
1.88 | 1.47 | 1.16 |
|
5yr Average Asset Turnover Ratio
|
0.94 | 0.58 | 0.69 |
|
5yr Avg Net Profit Margin
|
4.15 % | 10.0 % | 28.95 % |
|
Price to Book
|
2.15 | 2.65 | 5.4 |
|
P/E
|
44.52 | 79.29 | 31.42 |
|
5yr Avg Cash Conversion Cycle
|
37.07 Days | 13.14 Days | 57.55 Days |
|
Inventory Days
|
68.72 Days | 66.66 Days | 26.01 Days |
|
Days Receivable
|
99.71 Days | 122.66 Days | 50.74 Days |
|
Days Payable
|
143.26 Days | 257.34 Days | 75.73 Days |
|
5yr Average Interest Coverage Ratio
|
3.96 | 10.36 | 75.33 |
|
5yr Avg ROCE
|
13.52 % | 12.12 % | 30.18 % |
|
5yr Avg Operating Profit Margin
|
12.21 % | 16.84 % | 36.73 % |
|
5 yr average Debt to Equity
|
0.39 | 0.14 | 0.02 |
|
5yr CAGR Net Profit
|
10.7 % | -6.51 % | 17.49 % |
|
5yr Average Return on Assets
|
4.02 % | 5.75 % | 19.63 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
33.26 % | 43.16 % | 73.6 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.44 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Zim Laboratories
|
Medicamen Biotech
|
Prevest Denpro
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Capex
|
Capex
|
-
|
-
|
|
Customer Segment
|
Customer Segment
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|